RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.
RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.